Pharmacokinetics of a Novel Anagrelide Extended-Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product.

about

Pharmacokinetics of a Novel Anagrelide Extended-Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product.

Item

http://www.wikidata.org/entity/Q49784463

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pharmacokinetics of a Novel An ...... ison With a Reference Product.

@en

Pharmacokinetics of a Novel An ...... ison With a Reference Product.

@nl

type

Item

label

Pharmacokinetics of a Novel An ...... ison With a Reference Product.

@en

Pharmacokinetics of a Novel An ...... ison With a Reference Product.

@nl

prefLabel

Pharmacokinetics of a Novel An ...... ison With a Reference Product.

@en

Pharmacokinetics of a Novel An ...... ison With a Reference Product.

@nl

P1476

Pharmacokinetics of a Novel An ...... rison With a Reference Product

@en

P2093

Bernd Jilma

http://www.w3.org/2001/XMLSchema#string

Christoph S Klade

http://www.w3.org/2001/XMLSchema#string

Petro E Petrides

http://www.w3.org/2001/XMLSchema#string

Rudolf Widmann

http://www.w3.org/2001/XMLSchema#string

P2860

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans.

Anagrelide: a new drug for treating thrombocytosis.

Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers.

Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia.

Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.

Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.

Cardiovascular safety of anagrelide in healthy subjects: effects of caffeine and food intake on pharmacokinetics and adverse reactions

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.

P304

123-131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CPDD.340

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christian Schoergenhofer

P577

2017-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28301098

http://www.w3.org/2001/XMLSchema#string

P932

5811889

http://www.w3.org/2001/XMLSchema#string